Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163747 · ClinicalTrials.gov registry record · Phase 4
A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
A Phase 4 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 4
- Development phase
- 91
- Enrollment target
NCT01163747 is a Phase 4 study that has completed, run by Genentech. The registered enrollment target is 91 participants.
The verdict
NCT01163747, a Phase 4 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 91 participants
- Enrollment target
Study Summary
This randomized, parallel-group, open-label study will evaluate the effect of Actemra (tocilizumab) on vaccination in patients with active rheumatoid arthritis who have an inadequate response to methotrexate and who have had an inadequate clinical response or were intolerant to treatment with one or more anti-tumor necrosis factor (anti-TNF) therapies.
Interventions
- DRUG methotrexate
- BIOLOGICAL tocilizumab
- BIOLOGICAL 23-Valent Pneumococcal Polysaccharide Vaccine
- BIOLOGICAL Tetanus Toxoid Adsorbed Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01163747
The ClinicalTrials.gov registry entry for NCT01163747 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which methotrexate is the first listed.
NCT01163747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01163747 about?
NCT01163747 is a clinical study titled "A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)". This randomized, parallel-group, open-label study will evaluate the effect of Actemra (tocilizumab) on vaccination in patients with active rheumatoid arthritis who have an inadequate response to methotrexate and who have had an inadequate clinical response or were intolerant to treatment with one or...
What is the current status of trial NCT01163747?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 91 participants. The study started on 2010-09. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01163747?
The interventions under investigation include: methotrexate (DRUG), tocilizumab (BIOLOGICAL), 23-Valent Pneumococcal Polysaccharide Vaccine (BIOLOGICAL), Tetanus Toxoid Adsorbed Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01163747?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.